Mirum reports preliminary Q1 2023 revenue of $31.5M, cash $232.1M; updates VISTAS trial timeline

Mirum Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.80 revenue$31,598,000

Preliminary Q1 2023 total revenue ~$31.5M, product sales net ~$29M, license revenue ~$2.5M.
Cash, cash equivalents and short-term investments ~$232.1M as of March 31, 2023.
Operating expenses consistent to moderately increased versus Q4 2022.
VISTAS Phase 2b (volixibat in PSC) blinded interim analysis now expected H2 2023.
VANTAGE Phase 2b (PBC) interim and EMBARK Phase 2b (biliary atresia) topline data remain on track for H2 2023.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Mirum Pharmaceuticals, Inc. reported first quarter of 2023 results: revenue approximately $31.5 million of total revenue, consisting of approximately $29.0 million of product sales, net, and appro.

Period: first quarter of 2023
Revenue: approximately $31.5 million of total revenue, consisting of approximately $29.0 million of product sales, net, and appro
Result: preliminary results

Exact text from the filing

The company’s preliminary unaudited financial results for the first quarter of 2023 include: • Approximately $31.5 million of total revenue, consisting of approximately $29.0 million of product sales, net, and approximately $2.5 million of license revenue, for the three months ended March 31, 2023;

View on SEC.gov

Browse all earnings releases →

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-098423

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.